T0	Outcomes 198 223	efficacy and tolerability
T1	Outcomes 764 775	discretion.
T2	Outcomes 776 800	The primary endpoint was
T3	Outcomes 847 893	secondary endpoints were changes from baseline
T4	Outcomes 1206 1216	p < 0.001)
T5	Outcomes 1303 1335	weight vs placebo (all p < 0.01)
T6	Outcomes 1392 1406	blood pressure
T7	Outcomes 1439 1476	percentages of patients had confirmed
T8	Outcomes 1582 1604	15 and 12% of patients
T9	Outcomes 1712 1732	and 5%, respectively
T10	Outcomes 1734 1759	CONCLUSIONS Empagliflozin
T11	Outcomes 1764 1787	78 weeks added to basal